

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) Oxaliplatinum stable pharmaceutical preparation for parenteral administration, characterized in that the oxaliplatinum is contained in a solution in a solvent at a concentration of at least 7 mg/ml and in that said solvent comprises a sufficient quantity of a hydroxylated derivative selected among 1,2-propanediol, glycerol, maltitol, saccharose and inositol.
2. (Original) Pharmaceutical preparation according to claim 1, characterized in that the oxaliplatinum is contained in a solution in said solvent at a concentration of at least 9 mg/ml and in that 1 ml of said solvent comprises at least 100 mg of one or several of said hydroxylated derivatives.
3. (Currently Amended) Pharmaceutical preparation according to claim 2, characterized in that said solvent does not comprise ~~comprises besides~~ water.
4. (Original) Pharmaceutical preparation according to claim 3, characterized in that the oxaliplatinum is contained in a solution in said solvent at a concentration comprised between about 10 mg/ml and about 15 mg/ml.
5. (Previously Amended) Pharmaceutical preparation according to claim 1, characterized in that it is packed in an appropriate container for parenteral administration.
6. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a multidoses flask.
7. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a prefilled syringe.

8. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is a soft perfusion bag.
9. (Original) Pharmaceutical preparation according to claim 5, characterized in that said container is an ampoule.
10. (Previously Amended) Method for the preparation of a pharmaceutical preparation according to claim 1 comprising a step of mixing oxaliplatinum with a solvent comprising a sufficient quantity of at least one hydroxylated derivative selected among 1,2-propanediol, glycerol, maltitol, saccharose and inositol.
11. (Currently Amended) Method according to claim 10, characterized in that it comprises the following steps:
 - a) put in contact at a temperature less than ~~inferior to~~ 80°C a quantity of oxaliplatinum with a sufficient quantity of the said solvent to obtain an oxaliplatinum concentration of at least 7 mg/ml;
 - b) establish the mixture obtained at the step a) at a temperature comprised between 15-30°C;
 - c) submit the mixture obtained at the step b) to an aseptic filtration; and
 - d) the conservation in an adapted container for a parenteral administration of the mixture obtained at the step c) at a temperature comprised between 2-30°C.
12. (Cancelled).
13. (Cancelled).
14. (Cancelled)
15. (New) A multidoses flask containing the pharmaceutical preparation according to claim 1.

16. (New) A prefilled syringe containing the pharmaceutical preparation according to claim

1.

17. (New) A soft perfusion bag containing the pharmaceutical preparation according to

claim 1.